Balt has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic subdural hematoma (cSDH).

The trial will evaluate the safety and effectiveness of the middle meningeal artery (MMA) embolisation with the Squid liquid embolic device for the management of cSDH in both surgical and non-surgical patients.

Balt CEO Pascal Girin said: “The approval of the IDE for the STEM trial represents a significant milestone for Balt as this will be our first prospective study in the United States and represents our commitment to investing in clinical trials that will deliver answers to currently unresolved clinical questions.”

cSDH is a common disease primarily seen in older adults. According to a recent Veterans Affairs (VA) study, cSDH has a prevalence rate of 79.4 per 100,000 people.

By 2030, the incidence rate of the disease in the US in the ageing VA and civilian populations is expected to reach 121.4 and 17.4 cases respectively.

Dr Adam Arthur and Dr David Fiorella are the co-primary investigators of the prospective, randomised and controlled multi-centre clinical trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dr Arthur said: “This is a disease, which affects a large number of people, and preys particularly on the elderly. Current treatment options are not well-studied and often require invasive surgeries and prolonged stays in the ICU.

“The STEM study will enable us to learn a tremendous amount about how to help these patients and how best to treat a major reversible cause of dementia and disability in the elderly.”